Pooled evidence from cohort studies of patients treated with biologic therapy for rheumatoid arthritis, IBD and psoriasis does not show a statistically significant increased risk of melanoma, a study shows.

However, because the systematic review and meta-analysis found trends toward increased melanoma rates with long-term therapy, a clinically meaningful increase in risk cannot be ruled out, the investigators say.